September 14, 2010. If a device can kill you if it fails, or if it doesn’t work accurately, then it should be considered a high-risk device, not just a high-risk recall.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter to Thomas Abrams about Continued Misleading Ads for Seroquel XR
August 23, 2010. When we first complained about these ads in January, Seroquel was approved for schizophrenia and for psychosis associated with bipolar disorder.
Read More »NCHR Testimony at the Chronic Hazard Advisory Panel (CHAP) on Phthalates
July 26, 2010. Phthalates have been shown to cause adverse health effects. Due to the fact that safe alternatives to phthalates are available now, we urge industry to switch to these alternatives.
Read More »Patient, Consumer, and Public Health Coalition Comments to FDA on Direct-to-Consumer Prescription Drug Advertisements
June 28, 2010. These proposed changes are steps in the right direction, but we continue to have strong reservations about direct-to-consumer prescription drug ads, and we will continue to urge Congress to restrict or ban them.
Read More »Patient, Consumer, and Public Health Coalition Comments to the FDA on “Food Additives; Bisphenol A”
June 4, 2010. There are many unanswered questions about the risks of BPA on human health, especially prenatal exposures, infants, and children.
Read More »